INTRODUCTION
Acute megakaryoblastic leukemia (AMKL) accounts for~10% of childhood acute myeloid leukemia (AML). Clinical outcomes are variable, ranging from 480 to o 40% in patients with or without Down syndrome, respectively. [1] [2] [3] [4] [5] [6] Genomically, Down syndrome AMKL is characterized by a founding GATA1 mutation that cooperates with trisomy 21, followed by the acquisition of additional somatic mutations in epigenetic and kinase signaling genes. [7] [8] [9] To gain insight into the genetic etiology of AMKL patients without Down syndrome, we previously performed transcriptome sequencing on diagnostic blasts from a discovery cohort of 14 pediatric cases and substantiated our findings in a recurrency/validation cohort. This analysis confirmed the unique biology of this disease as evidenced by novel fusion transcripts including CBFA2T3-GLIS2, GATA2-HOXA9, MN1-FLI1 and NIPBL-HOXB9. 10 To confirm their role in oncogenesis and gain insight into the mechanism whereby these novel fusions promote disease, we introduced each of them as well as their individual gene counterparts into murine hematopoietic progenitor cells that were assessed in murine syngeneic transplantation models. Accompanying histological, immunophenotypic and genomewide molecular characterization of resultant tumors delineated common and unique modes of leukemogenesis.
MATERIALS AND METHODS

Nucleotide sequencing
RNA and DNA library construction for transcriptome and whole-exome DNA sequencing were done as per manufacturer's instructions using the Illumina True-seq RNA sample preparation V2 and Agilent SureSelect MOUSE XT2 all exon 50 Mb kits. Sequencing was completed on the Illumina HiSeq 2000 (San Diego, CA, USA). Analysis of data that includes mapping, coverage, quality assessment, single-nucleotide variations/Indel detection and prediction of deleterious effects of missense mutations have been described previously. [10] [11] [12] Please see Supplementary Methods for details regarding use of transcriptome sequencing data in gene expression analyses. All sequencing data has been deposited in the GEO database, accession number SRP100343.
Murine bone marrow transplantation and colony-forming assays
All experiments involving mice were reviewed and approved by the Institutional Animal Care and Use Committee. Bone marrow from 4-6-week-old female C57BL/6 mice was harvested, lineage depleted and cultured in the presence of cytokines for 24 h prior to transduction on RetroNectin (Takara Bio Inc., Kyoto, Japan). Ecotropic envelopepseudotyped retroviral vectors were produced as previously described. 13 For colony-forming assays, cells were harvested 48 h following transduction, sorted for vector-encoded mCherry or GFP expression, and plated on methylcellulose containing cytokines (Stem Cell Technologies, Vancouver, BC, Canada). Colonies were counted after 7 days of growth at 37°C, harvested and serially replated. For primary bone marrow transplants, 4-8 × 10 6 unsorted cells were injected intravenously on day 0. An aliquot of cells was retained to determine transduction efficiencies and dosage of fusion protein-positive cells per mouse (Supplementary Methods). Recipient mice were conditioned with total body irradiation at a dose of 1100 rads divided on days − 1 and 0. For secondary transplants, 3-5 × 10 6 splenic cells from moribund mice were isolated and injected intravenously into recipient mice conditioned with 600 rads. DAPI) for analysis using FACS LSR II D (BD Biosciences, San Jose, CA, USA). Sorting was done on a FACSAria III (BD Biosciences). For a list of antibodies used, please see Supplementary Methods.
Histology
Tissues were fixed in 10% buffered formalin, embedded in paraffin and sections stained with hematoxylin and eosin.
Array-based comparative genomic hybridization of mouse tumors
The Mouse Genome CGH 244 K microarray (G4415A; Agilent, Santa Clara, CA, USA) was customized as previously described. 14, 15 Array hybridization was performed according to the manufacturer's recommended protocols. The circular binary segmentation algorithm implemented in the DNAcopy package from Bioconductor was applied to the normalized log2 ratio data to identify copy-number alterations for each tumor sample. 16, 17 aCGH data has been deposited in the GEO database, accession number GSE95081.
RESULTS AMKL chimeric transcripts enhance cellular self-renewal and induce leukemogenesis Approximately 50% of AML cases carry cytogenetic aberrations leading to fusion genes, many of which promote oncogenesis through the acquisition of enhanced cellular self-renewal. 18 To evaluate the effects of the CBFA2T3-GLIS2, GATA2-HOXA9, MN1-FLI1 and NIPBL-HOXB9 gene fusions, we introduced each of them into murine hematopoietic cells and assessed their effect on in vitro colony replating (Supplementary Figure S1) . Expression of each of the fusion genes resulted in a marked increase in self-renewal capacity, with colony formation persisting through 10 replatings. Immunophenotypic analysis revealed evidence of megakaryocytic differentiation in CBFA2T3-GLIS2 and MN1-FLI1 cohorts, whereas NIPBL-HOXB9 and GATA2-HOXA9 cells expressed myeloid progenitor markers (Supplementary Figure S3) . Transplantation of fusion gene-modified bone marrow cells into syngeneic recipients induced overt leukemia in all cohorts with the exception of CBFA2T3-GLIS2, suggesting that there is an essential requirement for cooperative mutation(s) in cases expressing this chimeric gene (Figure 1a) . At the time of clinical illness, blood counts revealed leukocytosis, anemia and thrombocytopenia (Supplementary Figure S4) . Necropsy of moribund mice revealed neoplastic infiltrates throughout all organs assessed including the peripheral blood, bone marrow, spleen, lymph nodes, liver, central nervous system, kidneys and lungs confirming the systemic nature of the disease (Figure 1b ; Supplementary Table S1 ). Tumor cells with megakaryocytic features by morphology were present at a low frequency in NIPBL-HOXB9 bone marrow sections, in contrast to MN1-FLI1 leukemias that were uniformly megakaryocytic (Figure 1b) . Although GATA1-HOXA9 leukemias did not demonstrate megakaryocytic morphology, immature and dysplastic megakaryocytes were interspersed throughout the bone marrow, a finding that is absent in classical AML mouse models such as those driven by PML-RARA and MLL-AF9 fusion genes (Figure 1b) . 19, 20 Consistent with immunophenotyping of colonyforming units, MN1-FLI1 tumors demonstrated the presence of megakaryocytic markers, whereas NIPBL-HOXB9 and GATA2-HOXA9 cells carried markers consistent with myeloid progenitors (Supplementary Figure S5) . Secondary transplants of all leukemias generated disease with shorter latencies than those observed in the primary transplant setting (Supplementary Figure S6) , implying selection for more aggressive leukemic clones. We conclude that MN1-FLI1, NIPBL-HOXB9 and GATA2-HOXA9 induce AML with megakaryocytic features in mice.
Fusion-driven leukemias carry cooperating mutations To characterize the tumors at the molecular level, five primary leukemic samples carrying each of the three fusions were subjected to array comparative genomic hybridization and whole-exome DNA sequencing ( Table S2) . Samples demonstrated a small number of cooperating mutations with 1.53 ± 0.42 copy-number alterations (range 0-6) and 5.7 ± 1.04 non-silent single-nucleotide variations/small insertion deletions (Indels; range 2-18) per case (Supplementary Table S4 ). Overall, cases carried an average of 7.27 ± 1.09 non-silent mutations (range 2-18). Of the non-silent single-nucleotide variations/Indels, only 2.33 ± 0.36 were expressed at the RNA level (range 1-5) and 1.2 ± 0.28 (range 0-3) of these were predicted to have a functional consequence (Supplementary Table S4 ). Thus the number of cooperating mutations in these tumors is extremely low, supporting the strength of the fusion genes in driving leukemogenesis. Despite this, recurrently mutated genes were identified. These include activating mutations in Flt3, Kras and cMet, as well as loss-of-function mutations in the tumor suppressors Phactr4, Wt1 and Tet2 (Supplementary Figure S7) . A comparison between fusion subtypes did not reveal any statistically significant differences in mutational frequency between the tumors induced by the three fusion genes (Supplementary Table S4 ).
Transcriptome sequencing identifies myeloid progenitor signatures and megakaryocytic features Transcriptome sequencing of tumor cohorts, along with 19 normal hematopoietic progenitor subsets spanning myeloid differentiation, confirmed unique gene expression patterns between normal and leukemic cells induced by each of the fusions (Supplementary Figure S9 ; Supplementary Methods). Gene set enrichment analysis of the leukemia signatures against the 19 normal hematopoietic progenitor subsets was consistent with immunophenotyping of the tumors. Specifically, MN1-FLI1 tumors were significantly enriched for the megakaryocyte progenitor signature, whereas NIPBL-HOXB9 and GATA2-HOXA9 were enriched for common myeloid progenitor and monocyte precursor signatures, respectively (Supplementary Figure S11) . Although immunophenotyping and gene set enrichment analysis of NIPBL-HOXB9 and GATA2-HOXA9 tumors suggested a lack of megakaryocytic features, our histological assessment demonstrated these tumors to have dysplastic and immature megakaryocytes present. Therefore we identified differentially expressed genes in megakaryocyte precursor subsets (MegDEGs) compared to other hematopoietic subsets and determined expression levels of these genes in our tumor populations (Table 1) . MN1-FLI1 leukemias shared the greatest similarity to megakaryocyte precursors, with elevated expression levels of 31-71% of MegDEGs. Despite the lack of megakaryocytic cell surface markers in NIPBL-HOXB9 and GATA2-HOXA9 tumors, these leukemias also shared 14-31% and 15-24% upregulated MegDEGs, respectively. To confirm that this enrichment was specific, we repeated this analysis using differentially expressed genes in polychromatic erythroblasts and found no enrichment in our leukemia subsets. The megakaryocyte erythroid progenitor subset of DEGs was most consistently shared with all fusions, ranging from 22 to 44% (Table 1) . Tjissen et al. 21 previously described a megakaryocytic transcriptional network defined by five transcription factors including GATA1, GATA2, RUNX1, FLI1 and TAL1 whose combinatorial pattern dictates target gene expression. To determine if the expression pattern of these five factors in our leukemia subtypes contributes to the specific megakaryocytic genes upregulated, we first evaluated their RNA levels when compared to normal hematopoietic subsets (Figure 3a) . NIPBL-HOXB9 and GATA2-HOXA9 leukemias were characterized by elevated RUNX1 and FLI1 expression, whereas MN1-FLI1 leukemias highly expressed all five factors. Consistent with this hypothesis, we found megakaryocytic target genes upregulated by RUNX1 and FLI1 binding to be enriched in NIPBL-HOXB9 and GATA2-HOXA9 leukemias, whereas MN1-FLI1 leukemias demonstrated enrichment for genes bound by all combinations of the five transcription factors (Figure 3b) . We conclude that all three fusion genes invoke component(s) of the megakaryocytic gene expression program to varying degrees.
Myeloid leukemias have been shown to invoke hematopoietic progenitor gene expression programs. An unsupervised analysis of fusion gene-driven leukemias along with hematopoietic stem cell, common myeloid progenitor, granulocyte monocyte progenitor and megakaryocyte erythroid progenitor subsets revealed that our murine leukemias have a greater similarity to committed myeloid progenitors than to hematopoietic stem cells (Supplementary Figure S12A) . K-means clustering identified elements of the granulocyte monocyte progenitor and megakaryocyte erythroid progenitor signatures in all three subtypes (Supplementary Figure S12B) . Despite the closer relationship at the gene expression level to committed myeloid progenitors, elements of the hematopoietic stem cell program could still be identified in all three subtypes (Supplementary Figure S12B) .
All three fusion constructs contain DNA-binding domains of genes known to play a role in malignancy. To determine if known targets of these genes were uniquely upregulated in the corresponding leukemias, genes differentially upregulated between the three subtypes were identified for gene set enrichment analysis. Accordingly, gene sets derived from hematopoietic cells transduced with EWSR1-FLI1, HOXA9 plus MEIS1 or GATA2 were significantly enriched in the MN1-FLI1 and
GATA2-HOXA9
subsets, respectively (Supplementary Figure S12A) . [22] [23] [24] As both NIPBL and HOXB9 proteins play a role in binding to regulatory regions of genes, we extracted a unique gene set derived from genome-wide NIPBL ChIP sequencing data in embryonic stem cells. 25 Greater than 6000 genomic loci were bound by NIPBL in this data set. About 479 of these loci were expressed in our leukemias and contained HOXB9 consensus binding sites as determined by MATCH analysis (Supplementary Figure S13B ; Supplementary Table S4 ). Upregulation of these 479 gene targets was highly enriched in NIPBL-HOXB9 leukemias in contrast to NIPBL targets that lacked a strong HOXB9 consensus-binding site, demonstrating cooperativity between these proteins in targeting the fusion to genomic loci (P = 0.006 vs P = 0.249). Interestingly, the top leading edge genes in this analysis revealed the oncogenes cMyc and Myb, as well as several Ras-associated guanine exchange factors and GTPases suggesting that the NIPBL-HOXB9 fusion protein is able to upregulate expression of canonical AML oncogenic pathways (Supplementary Figure S13B) . We conclude that leukemias driven by MN1-FLI1, GATA2-HOXA9 and NIPBL-HOXB9 carry components of megakaryocytic and myeloid progenitor gene expression signatures consistent with their differentiation block/ self-renewal phenotype seen in colony-forming unit assays as well as common and unique leukemia-specific gene expression signatures. Fusion genes have a unique function independent of their individual counterparts A common characteristic between all three fusions is the presence of protein interaction domains contributed by the N-terminal partner, and DNA-binding domains contributed by the C-terminal moiety (Supplementary Figure S1) . To determine if these fusions have a novel gain of function distinct from their individual counterparts, we introduced each partner gene into murine bone marrow cells for colony-forming unit and transplantation experiments. MN1, HOXA9 and HOXB9 genes all conferred the ability of transduced cells to serially replate, whereas FLI1 and GATA2 genes did not (Supplementary Figure S14) . Similarly, introduction of the NIPBL exons 1-6 (NIPBL e1-6 ), the portion present in the fusion gene, failed to allow cells to serially replate (Supplementary Figure S14) . The introduction of MN1 into hematopoietic cells led to a highly penetrant leukemia as has been shown previously (Figure 4) . [26] [27] [28] In contrast MN1, HOXA9, HOXB9 and FLI1 all had 475% disease-free survival with few myeloid leukemias resulting from their overexpression, whereas GATA2 and NIPBL failed to induce any disease at all (Figure 4 ). Thus only MN1 overexpression is sufficient to induce reproducible disease, whereas other subgroups require both fusion partners for leukemogenesis.
NIPBL-HOXB9 requires interaction with MAU2 to induce leukemogenesis NIPBL has not been previously implicated in malignancy and introduction of the N-terminal portion failed to allow serial replating or induce leukemia. Therefore, to evaluate the role of NIPBL in our model we introduced two different single-nucleotide variations previously shown to disrupt binding of NIPBL to the cohesin component MAU2 (G15R, P29Q).
29 Surprisingly, these single alterations abrogated the ability of cells carrying the fusion to serially replate as well as to induce leukemia ( Supplementary  Figures S15A-B) . To verify interaction of the fusion with Mau2, we introduced the NIPBL-HOXB9 wild-type and mutant fusion constructs into NIH3T3 cells. Mau2 co-immunoprecipitated with wild-type but not mutant fusion constructs confirming this Figure S16) . Introduction of the Mau2 short hairpin RNA into leukemia cells transformed by NIPBL-HOXB9, followed by their in vitro culture resulted in extinction of cells lacking Mau2 expression in contrast to cells transduced with an empty vector or ineffective short hairpin RNAs, thereby demonstrating a strong selection bias against downregulation of Mau2 (Supplementary Figure S17A) . Furthermore, transplantation of flow-sorted NIPBL-HOXB9 leukemia cells expressing shMau2 into sublethally irradiated recipients resulted in a trend toward prolonged survival compared to controls (P = 0.04; Supplementary Figure S17B) . Analysis of the peripheral blood from mice that succumbed to leukemia in the Mau2 short hairpin RNA cohort revealed a loss of the knockdown construct with 460% of the blood consisting of single positive NIPBL-HOXB9 leukemia cells consistent with our in vitro results (Supplementary Figure S18) . We conclude that NIPBL plays a critical role in NIPBL-HOXB9-driven leukemogenesis, in part mediated by its interaction with Mau2, the component of the cohesin complex that recruits NIPBL to the genome. DISCUSSION AML is frequently driven by cytogenetic aberrations that lead to gene fusion events, the most common of which include MLL gene rearrangements, AML1-ETO, CBFB-MYH11 and PML-RARA. Despite evidence that these fusions are key genetic drivers of the malignancy, some fail to induce leukemia in murine models in the absence of a secondary event such as mutations driven by N-ethyl-N-nitrosourea, or in vitro manipulation with culture and cytokine support to select susceptible progenitor populations prior to transplantation. 30, 31 Although overexpression of ERG in a syngeneic transplant setting leads to megakaryoblastic leukemia, only one murine model based on genomic mutations that occur in patients with non-Down syndrome AMKL currently exists: that which models the RBM15-MKL1 fusion seen in infant AMKL. 32, 33 In this knock-in model, although all mice demonstrated evidence of hematopoietic dysregulation, only 2 out of 15 mice developed leukemia after a latency of 418 months.
interaction (Supplementary
We sought to establish additional and more efficient murine models for AMKL by evaluating four previously described fusion products identified in human cases by RNAseq.
10 NIPBL-HOXB9, GATA2-HOXA9 and MN1-FLI1 all induced acute leukemia with high penetrance and an average latency of 143 ± 76 days (range 47-435; Supplementary Methods). Surprisingly we saw few cooperating mutations by whole-exome DNA sequencing and array comparative genomic hybridization supporting the strength of their leukemic potential. Although all of the murine tumors analyzed had at least one additional mutation, a significant number of these are likely passenger mutations because they are not recurrent, are not predicted to have functional consequences -and HOXB9-transduced bone marrow was injected into lethally irradiated recipients. Leukemiafree survival is shown. Due to size restraints, the NIPBL e1-6 retroviral construct carries NIPBL exons 1-6, the portion of the gene involved in the fusion.
affecting the encoded protein, and fail to affect genes previously shown or predicted to play roles in malignancy (Supplementary  Table S3 ).
Of the three fusion genes, leukemias induced by MN1-FLI1 exhibited the strongest canonical megakaryocytic phenotype in the majority of mice (Figure 1b; Supplementary Figure S5 ). These tumors also manifested the strongest megakaryocyte progenitor gene expression signature (Figures 3a and b; Supplementary  Figure S11 ). This phenotype is not surprising, given the known role of FLI1 in megakaryopoiesis. Binding sites for FLI1 are present on enhancers of megakaryocyte-specific genes, and cooperative binding with GATA1 mediates synergistic expression. 34 Upregulation of FLI1 targets, however, is likely not the sole reason for this phenotype, as expression of EWSR1-FLI1 in hematopoietic cells leads to an erythroid leukemia. 22 Furthermore, MN1 alone led to a megakaryocytic phenotype in a significant proportion of mice and evidence suggests the N-terminal portion of MN1 plays a role in megakaryocyte differentiation (Supplementary Figure S19) . 28 Other groups have previously introduced the MN1 gene into murine bone marrow for syngeneic transplant models and did not see a propensity for megakaryocytic disease. [26] [27] [28] This difference may reflect transplant methodologies, as we did not use 5-fluorouracil to eliminate mature progenitor cells in the bone marrow, choosing instead to lineage deplete unstimulated marrow and limit in vitro cell culture to 72 h prior to transplantation. Thus the population of cells transduced with the oncogene in our study and those of others is likely non-identical.
In contrast to MN1-FLI1, the gene partners of the NIPBL-HOXB9 and GATA2-HOXA9 fusions do not suggest an obvious propensity toward AMKL. Despite this, we saw elements of the megakaryocyte erythroid progenitor gene expression program in both subtypes, a finding that is absent in MLL-AF9-driven leukemia. 35 In addition, tumor cells with megakaryocytic features were present upon histological analysis of NIPBL-HOXB9 leukemias, whereas GATA1-HOXA9 mice demonstrated abundant immature and dysplastic megakaryocytes interspersed among the tumor cells. Thus these models both demonstrate features of megakaryoblastic disease albeit not to the extent of MN1-FLI1. Both NIPBL-HOXB9 and GATA2-HOXA9 fusions demonstrated a gene expression program consistent with upregulation of HOX target genes. The role of HOX genes in AML has been well established and thus the resultant murine leukemias that carry a predominantly myeloid phenotype are perhaps not unexpected. 36 RNAseq analysis of a large pediatric AML cohort has not yet been published, thus it may be that these fusions exist in non-AMKL disease and are not specific to the AMKL subtype per se. Nonetheless, we have identified additional cases of NIPBL-HOXB9 and GATA1-HOXA9 in an expanded pediatric AMKL cohort by RNAseq, strengthening their association with this disease. 37 Similar to their frequency in human hematopoietic malignancies, Flt3-and Kras-activating mutations were identified in 20% and 13% of mouse leukemias, respectively (Supplementary Figure S8 ; Supplementary Table S2) . 38, 39 The identification of these mutations serve to not only validate the applicability of our mouse models in studying human disease, but also provides direct functional evidence of their role in the progression of disease. 40 Studies in humans and mice have shown that FLT3 plays an important role in AML, either through mutational activation or upregulation by chimeric oncogenes. 41, 42 NIPBL-HOXB9, GATA2-HOXA9 and MN1-FLI1 leukemias all upregulated Flt3 when compared to normal myeloid progenitors (Supplementary Figure S12C ; Supplementary Table S6 ). The promoter/enhancer region of Flt3 contains ETS-, HOX-and GATA-binding sites, providing a rationale for the ability of the three different fusion genes to uniformly increase Flt3 expression. 43, 44 In conclusion, we have generated a highly penetrant AMKL mouse model and two AML mouse models with megakaryocytic features, all of which have been characterized phenotypically and at the genomic level. Mechanistic studies have demonstrated that these chimeric oncogenes block maturation and enhance self-renewal through the upregulation of progenitor gene expression programs. With the exception of MN1, both fusion gene partners were required for full penetrance of disease. Cooperating mutations identified by next-generation sequencing were significant for activating kinase mutations that have previously been shown to confer cytokine independence. In summary, these models replicate many features of human AMKL, as evidenced by their clinical presentation and molecular characteristics. They provide valuable tools for future biological and therapeutic studies to further our understanding and improve outcomes of this rare and devastating subtype of leukemia.
